Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 6714 record(s)

Req # A-2020-000873

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-108397-469.

Organization: Health Canada

12 page(s)
March 2024

Req # A-2020-001076

Adverse Drug Reactions (ADRs) for Zenhale. Report numbers: 000687913, E2B_00037157, E2B_00282538, E2B_00356618, E2B_00785746, 000585164, 000335842, E2B_00356618, E2B_00785746. ADR for Zepatier. Report number: 000684523.

Organization: Health Canada

934 page(s)
March 2024

Req # A-2020-001078

Adverse Drug Reactions (ADRs). Report numbers: 000916615, 000916620, 000918479, E2B_03252887.

Organization: Health Canada

40 page(s)
March 2024

Req # A-2020-001136

Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: 000726947, E2B_03098060.

Organization: Health Canada

15 page(s)
March 2024

Req # A-2020-001202

Adverse Drug Reactions (ADRs). Report numbers: E2B_01925299, E2B_01965185, E2B_01984129, E2B_01971261, E2B_02013199, E2B 02047270, E2B_02058616, E2B_02057934, E2B_02063270, E2B_02065724, E2B_02069233, E2B_02077440, E2B_02077100, E2B_02083700, E2B_02083743, E2B 02079100, E2B_01986605, E2B_02084151, E2B_02094768, E2B_01916619.

Organization: Health Canada

332 page(s)
March 2024

Req # A-2020-001318

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-111487-77.

Organization: Health Canada

1 page(s)
March 2024

Req # A-2020-001319

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-111288-785.

Organization: Health Canada

38 page(s)
March 2024

Req # A-2020-001578

Adverse Drug Reactions (ADRs). Report numbers: E2B_03230117, E2B_03230219, E2B_03230378, E2B_03230441, E2B_03230613, E2B_03231580, E2B_03231683, E2B_03232416, E2B_03232901, E2B_03232917, E2B_03232925, E2B_03232932, E2B_03233614, E2B_03234560, E2B_03235183, E2B_03235576, E2B_03235732, E2B_03237252, E2B_03237370, E2B_03237435.

Organization: Health Canada

289 page(s)
March 2024

Req # A-2020-001852

Adverse Drug Reactions (ADRs). Report numbers: E2B_02810380, 000731396, E2B_02818125, E2B_02843420, E2B_02891039, E2B_02943083, E2B_03041828, E2B_03079630, E2B_03055551, E2B_03087521, E2B_03117437, E2B_03062342, E2B_03088541, E2B_02993422, 000920716, 000925885, E2B_03251851, E2B_03208513, E2B_03251536, 000720779.

Organization: Health Canada

524 page(s)
March 2024

Req # A-2020-001868

Adverse Drug Reactions (ADRs). Report numbers: 000719685, E2B_02205730, E2B_02141648, E2B_02349985, E2B_02405081, E2B_02488752, E2B_02074080, E2B_02060206, E2B_02119458, E2B_02233659, E2B_02063296, E2B_02941567, E2B_02900000, E2B_02524499, E2B_02935580, E2B_02837478, 000926298, E2B_02615695, E2B_02636153, E2B_02881059.

Organization: Health Canada

420 page(s)
March 2024
Date modified: